Clinical Trial: A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07905183) titled 'A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs' on Oct. 23.

Brief Summary: The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

Study Start Date: Dec. 31

Study Type: INTERVENTIONAL

Condition: Chronic Myeloid Leukemia (CML) Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive...